Zhao Rui-Heng, Han Jing, Han Ze-Lu, Zhang Shu-Hua, Lin Jiang-Tao
Graduate School, Beijing University of Chinese Medicine Beijing 100029, China Department of Respiratory and Critical Care, China-Japan Friendship Hospital Beijing 100029, China.
Graduate School, Beijing University of Chinese Medicine Beijing 100029, China.
Zhongguo Zhong Yao Za Zhi. 2022 Feb;47(4):1095-1102. doi: 10.19540/j.cnki.cjcmm.20210927.501.
This study aims to evaluate the effectiveness and safety of Suhuang Zhike Capsules in treating chronic obstructive pulmonary disease. The Chinese and English databases were searched(from the establishment to July 2021) for randomized controlled trials(RCTs) on the treatment of chronic obstructive pulmonary disease with Suhuang Zhike Capsules, yielding 130 articles and finally 12 eligible RCTs. The 12 RCTs enrolled a total of 1 159 patients(579 in experimental group, 580 in control group), with 728 males(62.8%) and 431 females(37.2%). Meta-analysis showed that the conventional western medicine combined with Suhuang Zhike Capsules increased clinical efficacy(OR=4.31, 95%CI[2.88, 6.46], Z=7.08, P<0.000 01), forced expiratory volume in one second(FEV1)(SMD=0.88, 95%CI[0.60, 1.16], Z=6.24, P<0.000 01), forced vital capacity(FVC)(SMD=0.96, 95%CI[0.38, 1.55], Z=3.22, P=0.001), forced vital capacity rate of one second(FEV1/FVC%)(SMD=0.85, 95%CI[0.51, 1.19], Z=4.92, P<0.000 01), and maximum voluntary ventilation(MVV)(SMD=0.61, 95%CI[0.39, 0.83], Z=5.40, P<0.000 01) compared with the conventional western medicine alone. The differences in residual volume/total lung capacity(RV/TLC)(SMD=-0.93, 95%CI[-3.38, 1.53], Z=0.74, P=0.46) and adverse reactions(OR=1.39, 95%CI[0.76, 2.56], Z=1.07, P=0.28) are insignificant. The study showed that the conventional western medicine combined with Suhuang Zhike Capsules could improve clinical efficacy and lung functions in the treatment of chronic obstructive pulmonary disease. In addition, the combination had been verified to be safe. However, in view of the uneven method quality, small sample size, and inconsistent outcome indicators of the included studies, higher-quality, multi-center, and large-sample RCTs are needed for further verification.
本研究旨在评价苏黄止咳胶囊治疗慢性阻塞性肺疾病的有效性和安全性。检索中文和英文数据库（自建库至2021年7月）中关于苏黄止咳胶囊治疗慢性阻塞性肺疾病的随机对照试验（RCT），共获得130篇文献，最终纳入12项合格的RCT。这12项RCT共纳入1159例患者（试验组579例，对照组580例），其中男性728例（62.8%），女性431例（37.2%）。Meta分析显示，与单纯使用传统西药相比，传统西药联合苏黄止咳胶囊可提高临床疗效（OR=4.31，95%CI[2.88，6.46]，Z=7.08，P<0.000 01）、一秒用力呼气容积（FEV1）（SMD=0.88，95%CI[0.60，1.16]，Z=6.24，P<0.000 01）、用力肺活量（FVC）（SMD=0.96，95%CI[0.38，1.55]，Z=3.22，P=0.001）、一秒用力肺活量率（FEV1/FVC%）（SMD=0.85，95%CI[0.51，1.19]，Z=4.92，P<0.000 01）和最大自主通气量（MVV）（SMD=0.61，95%CI[0.39，0.83]，Z=5.40，P<0.000 01）。残气量/肺总量（RV/TLC）（SMD=-0.93，95%CI[-3.38，1.53]，Z=0.74，P=0.46）和不良反应（OR=1.39，95%CI[0.76，2.56]，Z=1.07，P=0.28）差异无统计学意义。研究表明，传统西药联合苏黄止咳胶囊治疗慢性阻塞性肺疾病可提高临床疗效和肺功能。此外，该联合用药已被证实是安全的。然而，鉴于纳入研究的方法质量参差不齐、样本量小以及结局指标不一致，需要更高质量、多中心、大样本的RCT进行进一步验证。
